Intervention Review

Spironolactone for hypertension

  1. Josh Batterink1,
  2. Sarah N Stabler2,
  3. Aaron M Tejani3,*,
  4. Curt T Fowkes1

Editorial Group: Cochrane Hypertension Group

Published Online: 4 AUG 2010

DOI: 10.1002/14651858.CD008169.pub2


How to Cite

Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008169. DOI: 10.1002/14651858.CD008169.pub2.

Author Information

  1. 1

    Northern Health Authority, Pharmacy, Prince George, BC, Canada

  2. 2

    University of BC, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada

  3. 3

    Fraser Health Authority, Pharmacy Services, Burnaby, BC, Canada

*Aaron M Tejani, Pharmacy Services, Fraser Health Authority, 3935 Kincaid Street, Burnaby, BC, V5G 2X6, Canada. Aaron.Tejani@fraserhealth.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 4 AUG 2010

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter Bramlage, Stephanie L. Swift, Martin Thoenes, Joan Minguet, Carmen Ferrero, Roland E. Schmieder, Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease, European Journal of Heart Failure, 2016, 18, 1
  2. 2
    Ján Rosa, Tomáš Zelinka, Ondřej Petrák, Branislav Štrauch, Robert Holaj, Jiří Widimský, Should All Patients with Resistant Hypertension Receive Spironolactone?, Current Hypertension Reports, 2016, 18, 11

    CrossRef

  3. 3
    Julio César Jiménez Pérez, Araní Casillas Ramírez, Liliana Torres González, Linda Elsa Muñoz Espinosa, Marlene Marisol Perales Quintana, Gabriela Alarcón Galván, Homero Zapata Chavira, Francisco Javier Guzmán de la Garza, Carlos Rodrigo Cámara Lemarroy, Nancy Esthela Fernández Garza, Edelmiro Pérez Rodríguez, Paula Cordero Pérez, Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats, Oxidative Medicine and Cellular Longevity, 2016, 2016, 1

    CrossRef

  4. 4
    Leonard A. Mankin, Update in Hypertension Therapy, Medical Clinics of North America, 2016, 100, 4, 665

    CrossRef

  5. 5
    Hong Fan, Fujian Song, An assessment of randomized controlled trials (RCTs) for non-communicable diseases (NCDs): more and higher quality research is required in less developed countries, Scientific Reports, 2015, 5, 1

    CrossRef

  6. 6
    Jaap Deinum, Niels P. Riksen, Jacques W.M. Lenders, Pharmacological treatment of aldosterone excess, Pharmacology & Therapeutics, 2015, 154, 120

    CrossRef

  7. 7
    References, Kidney International Supplements, 2012, 2, 5, 405

    CrossRef

  8. 8
    Sarah C Masson, Aaron M Tejani, Sarah N Stabler, Matthew P Tsang, Tina SC Tam, May HY Wu, Anthony Tung, Angus Kinkade, Eplerenone for hypertension, The Cochrane Library,
  9. 9
    Tina SC Tam, May HY Wu, Sarah C Masson, Matthew P Tsang, Sarah N Stabler, Angus Kinkade, Anthony Tung, Aaron M Tejani, Eplerenone for hypertension, The Cochrane Library,
  10. 10
    Dane Gruenebaum, In people with hypertension, is there randomized controlled trial evidence to support the use of spironolactone?, Cochrane Clinical Answers,
  11. You have free access to this content11
    Rosa M Finizola, Elizabeth Infante, Bartolome Finizola, Jordi Pardo Pardo, Yris Flores, Ricardo Granero, Kaduo J Arai, Pharmacotherapy for hypertension-induced left ventricular hypertrophy, The Cochrane Library,